Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. (APLS) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · APLS · as of Sep 30, 2025
Ownership Breakdown
311
Institutional Holders
▲ 34 vs Q2
$3.34B
Total Inst. Value
▲ $1.05B vs Q2
128.02M
Shares Outstanding
freeFloat 81.70%
122.55M
13F Shares Held
▼ 9.14M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
APLS largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
AVORO CAPITAL ADVISORS LLC pharmaceutical preparations | 12.22M | 9.70% | 9.70% | $276.59B | Nov 14, 2025 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 9.99M | 7.92% | 7.92% | $226.01B | Nov 7, 2025 | ▼ 167.4K |
MORGAN STANLEY pharmaceutical preparations | 9.64M | 7.65% | 7.65% | $218.23B | May 27, 2026 | ▼ 109.0K |
WELLINGTON MANAGEMENT GROUP LLP pharmaceutical preparations | 9.29M | 7.37% | 7.37% | $210.25B | Nov 14, 2025 | ▲ 314.0K |
DEEP TRACK CAPITAL, LP pharmaceutical preparations | 8.00M | 6.35% | 6.35% | $181.05B | Nov 14, 2025 | ▲ 1.00M |
BLACKROCK, INC. pharmaceutical preparations | 6.27M | 4.97% | 4.97% | $141.86B | Nov 12, 2025 | ▼ 136.5K |
AQR CAPITAL MANAGEMENT LLC pharmaceutical preparations | 4.49M | 3.56% | 3.56% | $101.55B | Nov 14, 2025 | ▼ 1.49M |
JENNISON ASSOCIATES LLC pharmaceutical preparations | 4.35M | 3.45% | 3.45% | $98.40B | Oct 30, 2025 | ▲ 1.69M |
STATE STREET CORP pharmaceutical preparations | 4.04M | 3.20% | 3.20% | $91.37B | Nov 14, 2025 | ▲ 474.9K |
ECOR1 CAPITAL, LLC pharmaceutical preparations | 3.45M | 2.74% | 2.74% | $78.01B | Nov 14, 2025 | ▼ 8.45M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
26
Increased
+12.19M shares3
New Positions
first time holders15
Decreased
−15.84M shares0
Sold Out
fully exitedNet shares change (top 50)
3.65M
+12.19M / −15.84M
Net new holders
+14
3 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
APLS insider trading · insider activity
Source: SEC Form 4
36
Buy transactions
144
Sell transactions
0.25
Buy/Sell ratio
$8M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Dunlop A. Sinclair director | May 14, 2026 | D-Return | 3,544 | — | — | 0 | Form 4 ↗ |
Dunlop A. Sinclair director | May 14, 2026 | D-Return | 14,684 | $25.12 | $368.9K | 0 | Form 4 ↗ |
Dunlop A. Sinclair director | May 14, 2026 | D-Return | 27,600 | $30.62 | $845.1K | 0 | Form 4 ↗ |
Dunlop A. Sinclair director | May 14, 2026 | D-Return | 11,199 | $31.91 | $357.4K | 0 | Form 4 ↗ |
Dunlop A. Sinclair director | May 14, 2026 | D-Return | 8,554 | $47.28 | $404.4K | 0 | Form 4 ↗ |
Dunlop A. Sinclair director | May 14, 2026 | U-Tender | 161,567 | $4.00 | $646.3K | 0 | Form 4 ↗ |
Dunlop A. Sinclair director | May 14, 2026 | D-Return | 7,441 | $51.71 | $384.8K | 0 | Form 4 ↗ |
Dunlop A. Sinclair director | May 14, 2026 | D-Return | 27,600 | $57.20 | $1.58M | 0 | Form 4 ↗ |
Dunlop A. Sinclair director | May 14, 2026 | D-Return | 5,748 | $59.86 | $344.1K | 0 | Form 4 ↗ |
Chopas James George VP/Chief Accounting Officer | May 14, 2026 | Award | 16,150 | — | — | 16.1K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Apellis Pharmaceuticals, Inc. (APLS) is primarily owned by institutional investors, who hold approximately 95.7% of total shares outstanding. Company insiders own approximately 18.30%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Apellis Pharmaceuticals, Inc. is AVORO CAPITAL ADVISORS LLC, holding approximately 12.22 million shares — equal to 9.70% of outstanding shares — as of September 30, 2025.
A total of 311 institutional investors currently hold APLS stock, with a combined institutional value of approximately $3.34 billion as of the most recent 13F filing period.
Frequently asked questions
APLS ownershipApellis Pharmaceuticals, Inc. (APLS) is primarily owned by institutional investors, who hold approximately 95.7% of shares. The largest shareholder is AVORO CAPITAL ADVISORS LLC with a 9.70% stake. Company insiders hold 18.30%. Data sourced from SEC Form 13F as of September 30, 2025.